Pharmaceutical filing citing Obesity paper — Viking Therapeutics, 2026-02-11
Viking TherapeuticsViking TherapeuticsNASDAQ VKTX
Filings SEC · Quote Yahoo cited a paper published in Obesity in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month after the filing stood compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by Viking Therapeutics on 2026-02-11 was 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Obesity in the press release attached to it. Translating the sentence in the original document that cites the paper verbatim, it reads as follows.
Highlights from the Quarter and Year Ended December 31, 2025, and Other Recent Events: “The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio,” stated Brian Lian, Ph.D., chief executive officer of Viking.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company's claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has read only the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this extent.
The title of the paper is Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study and it was published in Obesity on 2026-01-08. The authors' affiliations are Louisville Metabolic and Atherosclerosis Research Center · Midwest Eye Institute · Conceptual Mindworks (United States) · Montana Technological University. The summary at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and a verified reading.
A phase 2 dose-finding trial administered a weekly injection for 13 weeks to adults who were obese or overweight, targeting both the GLP-1 and GIP receptors. Weight loss increased with higher doses, with more than 14 kilograms lost in the highest dose group, while the placebo group did not reach this level. Among those who received the real drug, more than nine out of ten lost more than one-twentieth of their body weight, compared to about one in eight in the placebo group. Side effects were primarily gastrointestinal symptoms, and the short duration of the trial did not allow for long-term effects to be assessed in this paper.
Details not addressed in the abstract remain in the full text and appendices. This article leaves gaps as they are. Readers are expected to determine which sentences in the abstract correspond to the company's cited excerpts by comparing the two citations above.
One month later, the stock price was in the top quarter of the sample.
The portion of return not explained by market movement is called excess return. Dates are counted as trading days, meaning the days the stock market is open. On a calendar, 20 trading days are approximately one month. The excess return for the day of the filing and the following month are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −1.4% | The extent of movement before the filing |
| On the filing day | +0.1% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +9.5% | One week |
| Accumulated over +1 to +20 trading days | +26.9% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +26.9% in this case is in the top quarter, corresponding to the 94% position from the bottom among 142 cases in the sample.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +18.7% | +26.9% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
After the regulatory filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed with only item numbers. In 8-K filings without titles, item numbers indicate the type of content. One can determine whether it was an earnings announcement or a contract based on the number. The details of what occurred are read in the original text of each link.
- 2026-04-29 8-K Item 2.02,9.01 — Earnings announcement · Financial statements · Attached documents
- 2026-05-26 8-K Item 5.07,9.01 — Shareholders' meeting results · Financial statements · Attached documents
- 2026-07-29 8-K Item 2.02,9.01 — Earnings announcement · Financial statements · Attached documents
What this article does not answer
This article, based only on abstracts, cannot answer what methods the papers used, what they reviewed, or what extent they demonstrated. How many times the cited paper was referenced afterward can be verified again using the citation count from OpenAlexOpenAlex
Data source · Website. What will be examined next is whether the company's subsequent 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has news to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to observe the movement of the company alone by removing the portion where the market as a whole rises or falls.
- Trading day
- A date counting only the days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to about a month on the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full paper, one cannot know the details and limitations of the method.